Literature DB >> 33268509

Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis.

Olivier Govaere1, Simon Cockell2, Dina Tiniakos1,3, Rachel Queen2, Ramy Younes1,4, Michele Vacca5, Leigh Alexander6, Federico Ravaioli1,7, Jeremy Palmer1, Salvatore Petta8, Jerome Boursier9, Chiara Rosso4, Katherine Johnson1, Kristy Wonders1, Christopher P Day1, Mattias Ekstedt10, Matej Orešič11, Rebecca Darlay12, Heather J Cordell12, Fabio Marra13, Antonio Vidal-Puig5, Pierre Bedossa1,14, Jörn M Schattenberg15, Karine Clément16, Michael Allison17, Elisabetta Bugianesi4, Vlad Ratziu14, Ann K Daly18, Quentin M Anstee18,19.   

Abstract

The mechanisms that drive nonalcoholic fatty liver disease (NAFLD) remain incompletely understood. This large multicenter study characterized the transcriptional changes that occur in liver tissue across the NAFLD spectrum as disease progresses to cirrhosis to identify potential circulating markers. We performed high-throughput RNA sequencing on a discovery cohort comprising histologically characterized NAFLD samples from 206 patients. Unsupervised clustering stratified NAFLD on the basis of disease activity and fibrosis stage with differences in age, aspartate aminotransferase (AST), type 2 diabetes mellitus, and carriage of PNPLA3 rs738409, a genetic variant associated with NAFLD. Relative to early disease, we consistently identified 25 differentially expressed genes as fibrosing steatohepatitis progressed through stages F2 to F4. This 25-gene signature was independently validated by logistic modeling in a separate replication cohort (n = 175), and an integrative analysis with publicly available single-cell RNA sequencing data elucidated the likely relative contribution of specific intrahepatic cell populations. Translating these findings to the protein level, SomaScan analysis in more than 300 NAFLD serum samples confirmed that circulating concentrations of proteins AKR1B10 and GDF15 were strongly associated with disease activity and fibrosis stage. Supporting the biological plausibility of these data, in vitro functional studies determined that endoplasmic reticulum stress up-regulated expression of AKR1B10, GDF15, and PDGFA, whereas GDF15 supplementation tempered the inflammatory response in macrophages upon lipid loading and lipopolysaccharide stimulation. This study provides insights into the pathophysiology of progressive fibrosing steatohepatitis, and proof of principle that transcriptomic changes represent potentially tractable and clinically relevant markers of disease progression.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Year:  2020        PMID: 33268509     DOI: 10.1126/scitranslmed.aba4448

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  45 in total

1.  Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH).

Authors:  Z Wang; Z Zhao; Y Xia; Z Cai; C Wang; Y Shen; R Liu; H Qin; J Jia; G Yuan
Journal:  J Endocrinol Invest       Date:  2022-02-28       Impact factor: 4.256

2.  Dysregulated RNA polyadenylation contributes to metabolic impairment in non-alcoholic fatty liver disease.

Authors:  Andrew M Jobbins; Nejc Haberman; Natalia Artigas; Christopher Amourda; Helen A B Paterson; Sijia Yu; Samuel J I Blackford; Alex Montoya; Marian Dore; Yi-Fang Wang; Alessandro Sardini; Inês Cebola; Johannes Zuber; Sheikh Tamir Rashid; Boris Lenhard; Santiago Vernia
Journal:  Nucleic Acids Res       Date:  2022-04-08       Impact factor: 16.971

3.  Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.

Authors:  Naoto Fujiwara; Naoto Kubota; Emilie Crouchet; Bhuvaneswari Koneru; Cesia A Marquez; Arun K Jajoriya; Gayatri Panda; Tongqi Qian; Shijia Zhu; Nicolas Goossens; Xiaochen Wang; Shuang Liang; Zhenyu Zhong; Sara Lewis; Bachir Taouli; Myron E Schwartz; Maria Isabel Fiel; Amit G Singal; Jorge A Marrero; Austin J Fobar; Neehar D Parikh; Indu Raman; Quan-Zhen Li; Masataka Taguri; Atsushi Ono; Hiroshi Aikata; Takashi Nakahara; Hayato Nakagawa; Yuki Matsushita; Ryosuke Tateishi; Kazuhiko Koike; Masahiro Kobayashi; Takaaki Higashi; Shigeki Nakagawa; Yo-Ichi Yamashita; Toru Beppu; Hideo Baba; Hiromitsu Kumada; Kazuaki Chayama; Thomas F Baumert; Yujin Hoshida
Journal:  Sci Transl Med       Date:  2022-06-22       Impact factor: 19.319

4.  Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver.

Authors:  Wenshu Tang; Jingying Zhou; Weiqin Yang; Yu Feng; Haoran Wu; Myth T S Mok; Lingyun Zhang; Zhixian Liang; Xiaoyu Liu; Zhewen Xiong; Xuezhen Zeng; Jing Wang; Jiahuan Lu; Jingqing Li; Hanyong Sun; Xiaoyu Tian; Philip Chun Yeung; Yong Hou; Heung Man Lee; Candice C H Lam; Howard H W Leung; Anthony W H Chan; Ka Fai To; John Wong; Paul B S Lai; Kelvin K C Ng; Simon K H Wong; Vincent W S Wong; Alice P S Kong; Joseph J Y Sung; Alfred S L Cheng
Journal:  Cell Mol Immunol       Date:  2022-05-20       Impact factor: 22.096

5.  Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs.

Authors:  Valérie Duvivier; Stéphanie Creusot; Olivier Broux; Aurélie Helbert; Ludovic Lesage; Kevin Moreau; Nicolas Lesueur; Lindsay Gerard; Karine Lemaitre; Nicolas Provost; Edwige-Ludiwyne Hubert; Tania Baltauss; Angelique Brzustowski; Nathalie De Preville; Julia Geronimi; Lucie Adoux; Franck Letourneur; Adel Hammoutene; Dominique Valla; Valérie Paradis; Philippe Delerive
Journal:  J Clin Exp Hepatol       Date:  2021-09-08

6.  A human liver chimeric mouse model for non-alcoholic fatty liver disease.

Authors:  Beatrice Bissig-Choisat; Michele Alves-Bezerra; Barry Zorman; Scott A Ochsner; Mercedes Barzi; Xavier Legras; Diane Yang; Malgorzata Borowiak; Adam M Dean; Robert B York; N Thao N Galvan; John Goss; William R Lagor; David D Moore; David E Cohen; Neil J McKenna; Pavel Sumazin; Karl-Dimiter Bissig
Journal:  JHEP Rep       Date:  2021-03-21

Review 7.  The Role of AKR1B10 in Physiology and Pathophysiology.

Authors:  Satoshi Endo; Toshiyuki Matsunaga; Toru Nishinaka
Journal:  Metabolites       Date:  2021-05-21

8.  Prediction of Srebp-1 as a Key Target of Qing Gan San Against MAFLD in Rats via RNA-Sequencing Profile Analysis.

Authors:  Bendong Yang; Jingyue Sun; Shufei Liang; Peixuan Wu; Rui Lv; Yanping He; Deqi Li; Wenlong Sun; Xinhua Song
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

9.  JFK Is a Hypoxia-Inducible Gene That Functions to Promote Breast Carcinogenesis.

Authors:  Ziran Yang; Xuehong Zhou; Enrun Zheng; Yizhou Wang; Xinhua Liu; Yue Wang; Yanpu Wang; Zhaofei Liu; Fei Pei; Yue Zhang; Jie Ren; Yunchao Huang; Lu Xia; Sudun Guan; Sen Qin; Feiya Suo; Jie Shi; Lijing Wang; Lin He; Luyang Sun
Journal:  Front Cell Dev Biol       Date:  2021-07-15

10.  SCFJFK is functionally linked to obesity and metabolic syndrome.

Authors:  Lin He; Ruorong Yan; Ziran Yang; Yue Zhang; Xinhua Liu; Jianguo Yang; Xujun Liu; Xiaoping Liu; Lu Xia; Yue Wang; Jiajing Wu; Xiaodi Wu; Lin Shan; Xiaohan Yang; Jing Liang; Yongfeng Shang; Luyang Sun
Journal:  EMBO Rep       Date:  2021-06-11       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.